Retrospective analysis of metastatic behaviour of breast cancer subtypes.
Retrospective analysis of metastatic behaviour of breast cancer subtypes.
复制标题
DOI：
10.1007/s10549-015-3352-0
复制
发表时间：
2015-04
影响因子：
3.8
通讯作者：
van de Vijver, Marc J.
中科院分区：
文献类型：
--
作者：
Savci-Heijink, C. Dilara;Halfwerk, Hans;Hooijer, Gerrit K. J.;Horlings, Hugo M.;Wesseling, Jelle;van de Vijver, Marc J.
在发生远处转移的乳腺癌患者中，临床病程（包括转移模式）存在显著差异。在这里，我们提出了一个回顾性研究的乳腺癌患者谁都发展了远处转移，重点是乳腺癌亚型和临床过程之间的关联，包括器官特异性转移。对263例转移性乳腺癌患者的组织微阵列（TMA）进行ER、PR、HER 2、EGFR、CK 5/6、CK 14、E-Cadherin、TP 53和Ki 67染色。肿瘤分为ER+/HER 2 −/Ki 67高、ER+/HER 2 −/Ki 67低、ER+/HER 2+、ER−/HER 2+和ER−/HER 2 −组。检索与转移模式、转移时间轴、全身治疗和生存相关的相关数据。使用logistic回归的多变量模型评估了位点特异性复发和患者/肿瘤特征之间的关联。发生远处转移的中位时间为30个月（范围0-15.3年）; 75.8%的远处转移发生在原发性肿瘤治疗后的前5年。ER−/HER 2 −肿瘤患者的中位总生存期为27个月; HER 2+肿瘤患者为52个月; ER+/HER 2 −/Ki 67高患者为76个月，ER+/HER 2 −/Ki 67低患者为79个月。骨是最常见的远处转移部位（70.6%），其次是肝（54.5%）和肺（31.4%）。内脏转移率为76.8%。ER−/HER 2 −肿瘤患者发生内脏转移的比例为81%，发生骨转移的比例为55.2%; HER 2+肿瘤患者发生内脏转移的比例为77.4%，发生骨转移的比例为69.8%; ER+/HER 2-/Ki 67高表达者中，75.7%发生内脏转移，87.8%发生骨转移，ER+/HER 2-/Ki 67高表达者中，75.7%发生内脏转移，87.8%发生骨转移Ki 67 low在76.9%中发生内脏转移，在73.1%中发生骨转移。在转移性乳腺癌患者中，肿瘤亚型与生存和远处转移模式相关。这些关联有助于个体患者的监测和治疗选择。
Among breast cancer patients who develop distant metastases, there is marked variability in the clinical course, including metastasis pattern. Here, we present a retrospective study of breast cancer patients who all developed distant metastases focusing on the association between breast cancer subtype and clinical course, including organ-specific metastasis. Tissue microarrays (TMAs) were assembled and stained for ER, PR, HER2, EGFR, CK5/6, CK14, E-Cadherin, TP53 and Ki67 for 263 breast cancer patients with metastatic disease. Tumours were classified into ER+/HER2−/Ki67high, ER+/HER2−/Ki67low, ER+/HER2+, ER−/HER2+ and ER−/HER2− groups. Relevant data related to metastasis pattern, metastasis timeline, systemic treatment and survival were retrieved. Associations between site-specific relapse and patient/tumour characteristics were assessed with multivariate models using logistic regression. Median time for development of distant metastasis was 30 months (range 0–15.3 years); 75.8 % of the distance metastases developed in the first 5 years after treatment of the primary tumour. Patients with ER−/HER2− tumours had a median overall survival of 27 months; those with HER2+ tumours of 52 months; those with ER+/HER2−/Ki67high of 76 months and those with ER+/HER2−/Ki67low of 79 months. Bone was the most common site for distant metastasis (70.6 %) followed by liver (54.5 %) and lung (31.4 %), respectively. Visceral metastasis was found in 76.8 % of the patients. Patients with ER−/HER2− tumours developed visceral metastases in 81 % and bone metastases in 55.2 %; those with HER2+ tumours developed visceral metastases in 77.4 % and bone metastases in 69.8 %; those with ER+/HER2−/Ki67high developed visceral metastases in 75.7 % and bone metastases in 87.8 % and those with ER+/HER2−/Ki67low developed visceral metastases in 76.9 % and bone metastases in 73.1 %. In metastatic breast cancer patients, tumour subtypes are associated with survival and pattern of distant metastases. These associations are of help in choices for surveillance and therapy in individual patients.
登录
查看更多内容
影响因子：
64.8
作者：
通讯作者：
--
DOI：
10.1038/newbio242148a0
发表时间：
1973-01-01
期刊：
NATURE-NEW BIOLOGY
影响因子：
--
作者：
FIDLER, IJ
通讯作者：
FIDLER, IJ
影响因子：
3.8
作者：
Hess, KR;Pusztai, L;Hortobagyi, GN
通讯作者：
Hortobagyi, GN
影响因子：
3.8
作者：
Harrell, J. Chuck;Prat, Aleix;Perou, Charles M.
通讯作者：
Perou, Charles M.
影响因子：
45.3
作者：
Dawood, Shaheenah;Broglio, Kristine;Giordano, Sharon H.
通讯作者：
Giordano, Sharon H.